Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pliant Therapeutics, Inc.

NASDAQ: PLRX · Life Sciences · 2 alerts · CIK 1746473

Share price
$0.6932Close, Nov 16
Market cap
$43M
Shares outstanding
61.99MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pliant Therapeutics, Inc. filings on SEC EDGAR ↗

4:12 PM ET 8-K
Financial Results

Pliant Therapeutics Financial Results

Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.

Term
Q3 2026

“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant
4:11 PM ET 10-Q
Financial Results

Pliant Therapeutics Q3 2026 Results: Net Loss of $24.4M, Loss Narrows

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics, with its lead candidate PLN-101095 currently in Phase 1a/1b trials. The company reports significant net losses since inception and expects to require substantial additional capital to fund its ongoing research and development activities.

Key figure
Net loss $24.4M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.